SimpleFunctions
Winner-take-all answer·3 source contracts·Kalshi 3·refreshed just now·Closes Jan 1, 2027 · 130d

When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List

Leader sits at 54% across 3 bound outcomes, runner-up at 35%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.

Leader probability

54%

Before 2027

runner-up 35¢leader 54¢

Outcomes

3

winner-take-all

Runner-up

35¢

Before November

Spread

19pp

contested

24h volume

$366

thin orderbook

Closes

Jan 1, 2027

130 days

Venue

Kalshi

3 bound

30-day trend

0%50%100%-30d-3w-2w-1wtodayBefore 2027: 43% (27 days, 17 points)Before 2027: 43% on 2026-08-23Before November: 37% (27 days, 21 points)Before November: 37% on 2026-08-22Before September: 3% (27 days, 23 points)Before September: 3% on 2026-08-20
Before 202743¢Before November37¢Before September3¢
Top 3 candidates by current price · 27d

Bracket family

How the bracket ladder is priced.

Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.

Analysis

This probability reflects market expectations that the FDA will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List before the end of 2026. The 46% price for a 2026 announcement versus 29% for one before November suggests traders see a meaningful but uncertain timeline. Key drivers include BPC-157's current regulatory status, pending FDA guidance or applications, and the agency's administrative capacity. The main catalyst would be an official FDA announcement or published guidance on BPC-157's reclassification. Without imminent regulatory signals, traders are pricing in genuine uncertainty about whether formal action occurs within the 5-month window remaining in 2026, versus pushing into 2027 or beyond.

  • BPC-157's current FDA classification and whether any formal reclassification petitions or applications are pending
  • The FDA's historical timeline for similar bulk drug substance reclassifications and current agency workload
  • Published or announced FDA guidance specifically addressing BPC-157's regulatory pathway
  • Market concentration risk: total 24-hour volume across three contracts is approximately $1,578, indicating moderate liquidity and potential information gaps
  • The gap between 'Before November' (29%) and 'Before 2027' (46%) suggests traders estimate only ~17 percentage points of probability mass for the December-January window

What moved the line

  • Aug 19Before 202725pp3257¢ · Kalshi
  • Aug 23Before 202714pp5743¢ · Kalshi
  • Aug 18Before September5pp116¢ · Kalshi
  • Aug 18Before November5pp4136¢ · Kalshi

Recently closed in general

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

More like this

Adjacent prediction questions.

How we compute these odds

SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.

For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.

Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.

Last updated on this page: just now.